PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial
Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
In the proposed trial the investigators will recruit women and men >65 years of age with
acute osteoporosis-related pelvic fractures and address 3 specific aims over 3 months of
treatment in a placebo controlled double blind study to determine if standard care and
teriparatide 20 mcg/day versus placebo for pelvic fractures:
1. Results in earlier evidence of cortical bridging on routine radiographs followed by
confirmatory Focus CT, a novel method to reduce radiation exposure from CT scans
(primary outcome).
2. Leads to a faster reduction in pain as assessed by both the Numeric Rating Scale and a
reduction in the use of narcotics (secondary outcome).
3. Leads more rapidly to improved functional outcome using a short physical performance
battery to assess lower extremity function (secondary outcome).
Phase:
Phase 2
Details
Lead Sponsor:
Helen Hayes Hospital Hospital for Special Surgery, New York
Collaborators:
Hospital for Special Surgery, New York Weill Medical College of Cornell University